Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Virus Replication, HIV-1, Didanosine, Drug Therapy, Combination, Stavudine, HIV Protease Inhibitors, Sensitivity and Specificity, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Viral Load, Reverse Transcriptase Polymerase Chain Reaction, Acute Infection
Eligibility Criteria
Inclusion Criteria Patients may be eligible for this study if they: Have early HIV infection or show recent seroconversion (going from HIV-negative to HIV-positive). Are at least 18 years old. Agree to 2 barrier methods of birth control, if heterosexually active men or women, during the study and for 3 months after. Exclusion Criteria Patients will not be eligible for this study if they: Have received prior antiretroviral therapy. Have received interferons, interleukins, colony-stimulating factors, radiation, cytotoxic chemotherapy, or HIV vaccines within 30 days prior to study entry. Have had any experimental therapy within 30 days prior to study entry. Are pregnant or breast-feeding. Patients will not be eligible for Group I if they: Have had pancreatitis (inflammation of the pancreas). Have received alpha tocopherol (vitamin E), amiodarone, astemizole, carbamazepine, cisapride, ergotamine/diergotamine, estrogens, fluvastatin, glucocorticoids, itraconazole, ketoconazole, midazolam, phenobarbital, phenytoin, quinidine, rifampin, rifabutin, sildenafil, statin drugs (simvastatin, pravastatin, atorvastatin) used for reduction of triglyceride or cholesterol levels, terfenadine, triazolam, or warfarin within 14 days of study entry. Have received chloramphenicol, cisplatin, clioquinol, dapsone, diphenylhydantoin, disulfiram, ethionamide, glutethimide, gold, hydralazine, isoniazid, metronidazole, pyridoxine, sodium cyanate, thalidomide, vincristine, or zalcitabine within 30 days of study entry. In certain cases, patients taking these drugs may still be eligible.
Sites / Locations
- Univ. of Colorado Health Sciences Ctr. AIEDRP
- AIDS Research Consortium of Atlanta, Inc. (ARCA) AIEDRP CRS
- Feinberg School of Medicine, HIV/ACTU AIEDRP CRS
- Rush Univ. Med. Ctr., Dept. of Infectious Disease AIEDRP CRS
- Centro de Referencia Estadual de AIDS AIEDRP